Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EC-InterCom

Financiado

Pyrimidine de novo synthesis in tumor endothelium: an overlooked target?

It sounds simple: A cell cannot divide without nucleotides. Indeed, the disruption of pyrimidine de novo synthesis (PDNS) efficiently blocks proliferation of cancer cells. Yet still today, PDNS-directed anticancer treatment has no... ver más

31/12/2024

IBT INSTITUTE OF B...

166K€

Presupuesto del proyecto: 166K€

Líder del proyecto

BIOTECHNOLOGICKY USTAV AV CR VVI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-12-31

HORIZON-WIDERA-2022-TALENTS-02-01: Fostering balanced brain circulatio... ExpectedOutcome:This action builds on the MSCA Postdoctoral Fellowships 2021 action (HORIZON-MSCA-PF...

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IBT INSTITUTE OF BIOTECHNOLO...

166.28K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-20832 CARACTERIZACION GENETICA DE LAS CANCER-STEM-CELLS (CSC) EN T... 36K€ Cerrado

De-CAF Decoding local crosstalk in tumor formation 184K€ Cerrado

MYCinTOPshape Mechanism and targeting of topoisomerase regulatory interact... 2M€ Cerrado

IJC2018-037657-I Angiogénesis y metabolismo en microentornos tumorales y angi... 93K€ Cerrado

REINFORCE TumoR microEnvIronment Normalization FOR enhanCed photodynam... 164K€ Cerrado

RTI2018-098968-B-I00 NUEVOS FACTORES IMPLICADOS EN EL FENOTIPO PSEUDO-ENDOTELIAL... 242K€ Cerrado

Duración del proyecto: 30 meses Fecha Inicio: 2022-06-14
Fecha Fin: 2024-12-31

Líder del proyecto

BIOTECHNOLOGICKY USTAV AV CR VVI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 166K€

Descripción del proyecto It sounds simple: A cell cannot divide without nucleotides. Indeed, the disruption of pyrimidine de novo synthesis (PDNS) efficiently blocks proliferation of cancer cells. Yet still today, PDNS-directed anticancer treatment has not entered clinics due to the lack of efficacy. Why? Cancer cells gain pyrimidines via PDNS or from salvage pathways, and PDNS inhibition in cancer cells can likely be bypassed by pyrimidines produced in the tumor environment or gained from the systemic circulation. Can we target this microenvironmental interaction to improve treatment efficacy? A crucial component of tumor environment are blood vessels. Tumors stimulate their growth, angiogenesis, to gain oxygen and nutrients. Metabolism of endothelial cells (ECs), the inner vessel lining, is rewired in tumors, and tumor ECs upregulate PDNS. However, whether and how elevated PDNS in ECs supports tumorigenesis is unknown. I hypothesize that PDNS in ECs affects tumor environment either directly by providing pyrimidines to cancer cells or indirectly by stimulating angiogenesis, making systemic resources more accessible to cancer cells. The central goals of this project are (i) to identify the metabolic communication of ECs with other cell types in tumors, (ii) asses if endothelial PDNS promotes angiogenesis, and (iii) to seek novel metabolic targets in ECs, whose inhibition improves efficacy of PDNS inhibitors in vivo. To reach these goals, I will use an inducible mouse model to selectively disable PDNS in the endothelium. With this unique tool available at my host institute, I will integrate a state-of-the-art multi-omics and my expertise in metabolism to disentangle the network of metabolic communication using a powerful combination of spatially resolved single cell transcriptomics, metabolomics and functional genomics. My innovative approach will open a way for understanding the EC contribution to metabolic balance in tumors with a potential to identify new metabolic anti-cancer strategies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores